Valenta Launches Five Observational Programs in Gastroenterology

Five observational programs studying the experience of using Valenta medications in gastroenterologists’ outpatient and inpatient practice begin in January 2017.

Their informational partners are Russian Gastroenterological Association (RGA) and Russian Scientific Liver Society (RSLS).

All the programs have been approved by the Local Ethics Committee of I.M. Sechenov First Moscow State Medical University or the Independent Interdisciplinary Ethics Committee on Ethical Review for Clinical Studies.

EXIT Observational Program for studying the experience of using Exportal® (lactitol) in inpatient and outpatient physicians’ daily practice when treating hepatic encephalopathy in patients with liver cirrhosis.

TREND Observational Program for studying the experience of using Trimedat® (trimebutine maleate) in inpatient and outpatient physicians’ daily practice when treating patients with functional dyspepsia.

TRIBUNE Observational Program for studying the experience of using Trimedat® (trimebutine maleate) in inpatient and outpatient physicians’ daily practice when treating patients with functional diseases of the gallbladder and bile ducts.

TERRA Observational Program for studying the practice of Teraligen® prescription for patients with the irritable bowel syndrome.

OsmоAid Observational Program for studying the outpatient practice of using osmotic laxatives in adult patients with chronic constipation.

It is planned to enroll a total of 500 patients into these observational programs.

In 2017, the program results are expected to be presented at key scientific events for gastroenterologists and general practitioners and in a series of publications in peer-reviewed scientific journals.